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(r=-0.235, p=0.039), meaning greater BV variability was associated 
with reduced LENT-SOMA bladder scores. 
Conclusions: We believe that we are the first to document an 
association between interfraction variation of bladder volume and 
long-term bladder toxicity outcomes in image-guided ICB for cervical 
cancer.This is consistent with previous data showing that BV variation 
can avoid overlap of high dose regions within the bladder. Such data 
could justify changing current practice in many centers that do not 
routinely use variable bladder filling protocols. Nonetheless, study is 
ongoing to determine the exact effect of BV changes on distribution of 
high dose areas to further validate this recommendation.  
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Purpose/Objective: Recent analysis of dosimetric variations 
occurring, e.g. due to anatomical variations, within and between 
different BT fractions, have revealed that expected intra- and inter-
fraction uncertainties are of the order of 10% for D90 of HR CTV and 
20-30% for D  for organs at risk, for the physical dose of each BT 
fraction (Nesvacil et al. 2012, Radiother Oncol 103, S2, S33). This 
leads to uncertainties in the total treatment dose by up to 4-7 Gy 
dose-response curves. The aim of this simulation study was to 
estimate this impact for target and OAR.  
Materials and Methods: In this numerical experiment, a dose-dose 
response curve was assumed for D90 of HR CTV and D  for OAR, by a 
logit function, corresponding to typical dose-response curves assessed 
from clinical data (e.g. Tanderup et al. (submitted) and Georg et al. 
(2009, Radiother Oncol 91, 173)). 
Dose response uncertainties were simulated by applying typical dose 
variations for HDR cervix BT in the calculations, and compared to the 
initial dose-response curve. 
A custom IDL script was used to simulate realistic total treatment 
dose values for a range of dose levels, taking into account reported 
standard deviations of intra-/inter-fraction variations, i.e., 10% for D90 
HR CTV ( / =10Gy) and 20% for D  of OAR ( / =3Gy), for a 
schedule with 45Gy EBRT and 4 BT fractions.  
For each dose level 10000 patients were simulated by picking 
uncertainties randomly for each BT fraction according to a N(Di, 2) 
distribution, where Di was the physical fractional dose and  the SD 
typical for variations. Simulated fractional doses were transformed 
For each simulated patient, response probabilities were calculated 
based on the assumed 'dose-response' curves for D90 and D . 
Parameters for the initial curves are given in Fig. 1. 
For each expected dose level, the corresponding calculated response 
probability values based on the simulated doses were plotted. Median 
and mean response probabilities of the simulated doses were 
graphically compared with expected response values at each dose 
level.  
 
 
Results: 
Results: In comparison to the expected dose-response curve, the 
simulations indicate a steeper slope in the low dose region and a 
flattening of the curve in the high-dose region. (Fig. 1) The effect is 
more visible in the case of OAR. 
Conclusions: Our preliminary simulations indicate that the predictive 
power of dose-effect relationships may be significantly influenced by 
dosimetric uncertainties. The steepness of the real dose-effect curve 
may be over- or underestimated depending on the investigated dose-
region. Taking into account random uncertainties, and minimizing 
them might lead to a relaxation of commonly used dose constraints 
for OAR, allowing for better coverage of target structures.  
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Purpose/Objective: Traditionally, vaginal dose points have been 
defined at the vaginal source level, thus not providing dose 
information for the entire vagina. Since reliable vaginal 
dosevolume/surface histograms are hardly available, a strategy for 
comprehensive vaginal dose reporting for combined external beam 
radiotherapy (EBRT) and brachytherapy (BT) was established. 
Materials and Methods: An anatomical vaginal reference point was 
defined at the level of the Posterior-Inferior Border of Symphysis 
(PIBS), plus two points at a distance of ±2cm (mid/introitus 
vagina)(Figure 1).For BT points were selected at 12/3/6/9 o'clock for 
the upper vagina, at the applicator ring surface and 5 mm depth 
(Figure 1). A vaginal reference length (VRL) was defined from ring 
centre to PIBS. Fifty-nine patients treated for cervical cancer were 
included into this retrospective feasibility study.  
 
 
Results: The method was applicable for all patients. The mean total 
51.4 Gy (36.6-91.7) and 5.7 Gy (1.7-49.1). At 5 mm depth from the 
ring, doses were respectively 115.4 Gy (53.2-210.7)/103.2 Gy (29.9-
Conclusions: With this novel system, a comprehensive reporting of 
vaginal doses is feasible. The present study has demonstrated large 
dose variations between patients observed in all parts of the vagina. 
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Purpose/Objective: Young women have a high rate of local failure 
after breast-conserving surgery (BCS) and radiation therapy (RT). We 
want to evaluate the efficacy and tolerability of 192-Ir high dose 
ratebrachytherapy (HDR) with a single fraction as a boost after whole 
breast irradiation in women aged 45 or less.  
Materials and Methods: We studied 167 consecutive patients (26-45 
years old) who underwent BCS and whole breast RT (46-50 Gy), for 
invasive breast cancer from 1999 to 2008. One-two weeks later, an 
implant with parallel metallic needles was performed under local 
anaesthesia and sedation in an outpatient basis. A free margin of at 
least 5mm was required. All cases were stages T1-2, 28.7% were pN+. 
Chemotherapy was used in 85% (adjuvant 67% and neoadjuvant 19%) 
and hormonal therapy in 77%. A single dose of 7 Gy (HDR) with 
optimization in volume was prescribed to the 90% isodose. Implant 
volume was decided by clinical assessment. No simulation or CT scan 
was performed, and dosimetry was calculated theoretically. The 
whole boost treatment was delivered in 2-3 hours, so we call it 'Fast-
boost'. 
Results: The median follow-up was 86 months. Nine patients relapsed 
in the tumour bed or in the margin of the implant with an actuarial 
local control at five and ten year of 95.7% (failure rate 4.3%). Another 
patient relapsed in a different quadrant, therefore actuarial breast 
control was 95.1%. Patients aged 40 or less had a breast failure rate of 
5.6% at ten year (compared with 13.5% of the EORTC 22881-10882 
trial). More local failures were seen in triple negative (13.6%), G3 
cases (8.9%), and patients aged 35 or less (11.5%). One patient 
developed an angiosarcoma. Eleven women required a mastectomy, 
then the preservation of breast was achieved in 94% of all patients. 
Twenty three patients developed distant metastasis. Disease free 
survival (DFS) at 5 and 10 year was 87.9% and 85.8% with overall 
survival of 92.1% and 87.3%. Ten-year DFS decreased in triple negative 
(75%) and G3 cases (76.4%). Cosmetic results were good or excellent 
in most cases (97%) and the acute and late toxicity was minimal. 
Conclusions: Fast-boost with a single fraction of HDR is a safe, quick, 
simple technique. Local control in women younger than 46 years old, 
when surgical margins are free, has been improved related to 
literature data, with few failures than expected at ten year. A better 
biological effect of HDR is suggested, and breast preservation in young 
women using this approach is recommended.  
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Purpose/Objective: To date there are only few data in the literature 
about the feasibility and efficacy of interstitial high-dose-rate (HDR) 
brachytherapy (BT) of base of tongue cancer.Therefore the aim of this 
prospective study was to contribute to this issue. 
Materials and Methods: Between January 1992 and June 2011sixty 
patients (mean age 57 years, range 36-78 years) with T1-4 and N0-3 
carcinoma of the base of tongue were presented. Fifty-six patients 
(93%) had advanced (stage III-IV) disease. Male/female ratio was 5/1. 
HDR BT boost (mean dose 17 Gy, range 12-30 Gy) was delivered after 
50 to 70 Gy (mean 62 Gy) locoregional external beam irradiation (EBI). 
Before 1996 the irradiation was performed by a Gammamed-IIi, since 
then by a Nucletron-Microselectron HDR (Ir-192) after-loading 
machine. In 10 cases rigid needle, in 50 cases flexible tube technique 
was applied. 
Results: The mean follow-up time for surviving patients was 121 
(range 20-229) months. The 5-year actuarial rate of local-, 
locoregional control and overall survival was 57%, 50% and 47%, 
respectively. Delayed soft tissue ulceration and osteoradionecrosis 
occurred in 8 (13%) patients.  
Conclusions: EBI combined with interstitial HDR BT boost results good 
local tumour control with low incidence of late side-effects in patients 
with advanced base of tongue carcinoma. Our results are similar to 
LDR data published in the literature. 
   
OC-0364   
Brachytherapy in the treatment of anal canal cancers: a large 
monocentric retrospective series. 
L. Lestrade1, B. De Bari2, P. Pommier3, X. Montbarbon1, E. Lavergne3, 
C. Carrie1 
1Centre Léon Bérard, Radiation Oncology Department, Lyon, France  
2AO Spedali Civili di Brescia - University of Brescia, Radiation 
Oncology Department, Brescia, Italy  
3Centre Léon Bérard, Unité de Biostatistique et d'Evaluation des 
Thérapeutiques, Lyon, France  
 
Purpose/Objective: To present one of the largest retrospective, long 
term analyses of anal canal cancer patients (pts.) treated with 
radiotherapy (RT) ± chemotherapy (CT), followed by a brachytherapy 
(BRT) boost. 
Materials and Methods: The primary and secondary endpoints of this 
analysis, as well all the variables analysed to study their potential 
impact on these endpoints are resumed in Table 1. 
 
 
 
Results: 
Treatment period: 05/1992 -12/2009. 
We treated 209 pts. (median age: 65 years; range: 26 – 89) with RT 
(58/209) or RT+CT (151/209). 163 pts. were stage II or IIIA (UICC 2002) 
and 58/209 were N1-3 at diagnosis. All pts. underwent a boost by a 
Low Dose Rate (LDR, 151 pts) or a Pulse Dose Rate (PDR, 58 pts) BRT. 
Median follow-up time was 73 months. 
Primary Endpoints: Local control (LC) and toxicity rates. 
Median LC time was not reached, with 5- and 10- years LC rates of 
78.6% and 73.9%, respectively. G3-G4 acute and late toxicity rates 
were 11.2% and 6.3%, respectively. Grade 3 CT related acute toxicities 
were recorded in 7/151 pts. (4.6%). Globally, treatment was 
temporarily (> 7 days) stopped in only 2 pts. and no patient 
definitively stopped the RT±CT treatment. 44/209 pts. (21%) 
underwent colostomy, 6/44 to treat a G4 ano-rectal toxicity. 
Sphincter function was evaluated with the Womack scale in the 
remaining 165 pts. and classified as score A (total continence) in 135 
pts. (82%), score B (incontinence to gazes) in 25 pts. (15%) and score C 
(incontinence to liquid stools) in 5 pts. (3%).  
Secondary endpoints: OS, CSS, DFS, NRFS, MFS. 
5-years OS, CSS, DFS, CFS, NRFS and MFS rates were 80.9%, 85.7%, 
69.4%, 79.3%, 82.1% and 90.5%, respectively. 
 10-years OS, CSS, DFS, CFS, NRFS and MFS rates were 65.7%, 81%, 
49.4%, 75.5%, 78.5% and 88.8%, respectively. 
Univariate and multivariate analysis. 
BRT dose statistically influenced the LC, with lower doses showing 
better outcomes (p = 0.003). We noted a statistical relation between 
the total BRT dose (<18Gy vs >18Gy) and the objective response at 
clinical evaluation before BRT, with higher doses delivered to pts. 
showing worse response (p = 0.001). LC statistically influenced all the 
considered secondary endpoints (p < 0.001). 
At the multivariate analysis, concomitant CT statistically influenced 
OS (p = 0.008) and MFS (p = 0.036) and the LC influenced OS and CSS 
(p < 0.001). A total dose < or >63Gy was the only variable significantly 
influencing the risk of G3-4 late toxicity (2.7% vs 10%, p=0.02). None 
of the other variables influenced the considered primary and 
secondary endpoints. 
Conclusions: BRT has an acceptable toxicity profile and allows high 
local control rates in anal canal pts. The role of this technique should 
be prospectively evaluated in the era of high conformal techniques 
and tailored oncologic treatments. 
 
 
 
 
 
